SIC ARGON - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 207,335 | 290,459 | 192,224 | 272,276 | 264,867 | 321,019 | 399,149 | 439,552 |
| Profit before tax | 6,441 | -355 | -80 | -30,511 | -15,947 | 2,141 | 3,635 | 6,010 |
| Net profit | 6,009 | -607 | -125 | -30,511 | -15,947 | 2,035 | 3,220 | 4,857 |
| Equity | 182,263 | 181,656 | 181,531 | 151,021 | 135,074 | 137,109 | 140,329 | 145,187 |
| Liabilities | 9,515 | 17,008 | 16,966 | 18,190 | 9,306 | 11,475 | 14,540 | 45,400 |
| Non-current assets | 2,608 | 2,681 | 2,525 | 3,071 | 5,761 | 4,024 | 19,955 | 18,248 |
| Current assets | 189,050 | 195,434 | 192,131 | 165,645 | 136,965 | 142,148 | 126,410 | 160,539 |
| Total assets | 191,658 | 198,115 | 194,656 | 168,716 | 142,726 | 146,172 | 146,365 | 178,787 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 61,015 | 75,041 | 90,042 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +27.6% | +40.1% | -33.8% | +41.6% | -2.7% | +21.2% | +24.3% | +10.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 3.1% | -0.3% | -0.1% | -18.1% | -11.2% | 1.4% | 2.2% | 2.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 3.3% | -0.3% | -0.1% | -20.2% | -11.8% | 1.5% | 2.3% | 3.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.9% | -0.2% | -0.1% | -11.2% | -6.0% | 0.6% | 0.8% | 1.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.1% | -0.1% | 0.0% | -11.2% | -6.0% | 0.7% | 0.9% | 1.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 69,112 | 96,820 | 64,075 | 96,099 | 132,434 | 160,510 | 199,575 | 219,776 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SIC ARGON - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-02-10 | 2025-02-10 | 8358.50 |
| 2025-01-26 | 2025-02-03 | 8358.50 |
| 2025-01-22 | 2025-01-22 | 8358.50 |
| 2025-01-16 | 2025-01-21 | 8357.22 |
| 2025-01-02 | 2025-01-02 | 75.08 |
| 2024-12-22 | 2024-12-31 | 75.08 |
| 2024-12-17 | 2024-12-20 | 75.08 |
| 2024-11-18 | 2024-12-03 | 75.08 |
| 2024-10-24 | 2024-11-04 | 91.32 |
| 2024-10-16 | 2024-10-23 | 90.90 |
| 2024-09-26 | 2024-10-01 | 90.91 |
SIC ARGON - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company SIC ARGON is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 0.46 |
| 2026-08-28 | 2026-08-30 | 0.08 |
| 2026-07-30 | 2026-08-26 | 0.08 |
| 2026-06-28 | 2026-07-07 | 0.08 |
| 2026-05-28 | 2026-06-05 | 4.0 |
| 2026-04-30 | 2026-05-25 | 4.0 |
| 2026-03-29 | 2026-04-22 | 4.0 |
| 2026-03-19 | 2026-03-22 | 4.0 |
| 2026-02-28 | 2026-03-12 | 4.0 |
| 2026-02-21 | 2026-02-21 | 4.0 |
| 2026-01-29 | 2026-02-20 | 0.12 |
| 2026-01-01 | 2026-01-22 | 0.12 |
| 2025-12-18 | 2025-12-18 | 129.0 |
| 2025-11-28 | 2025-11-30 | 0.6 |
| 2025-11-02 | 2025-11-24 | 0.6 |
| 2025-10-30 | 2025-11-01 | 0.39 |
| 2025-10-08 | 2025-10-23 | 0.39 |
| 2025-10-02 | 2025-10-07 | 128.67 |
| 2025-09-28 | 2025-10-01 | 128.28 |
| 2025-09-19 | 2025-09-23 | 128.28 |
| 2025-06-19 | 2025-06-23 | 16.28 |
| 2025-03-20 | 2025-03-20 | 24.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SIC ARGON, UAB (company code 302556575) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €439.6K, up 10.1% year on year and 36.9% over two years, showing a steady expansion trend. Net profit reached €4.9K, compared with €3.2K in 2024 and €2.0K in 2023, while the profit margin improved from 0.6% in 2023 to 0.8% in 2024 and 1.1% in 2025. The balance sheet also strengthened in 2025: total assets increased to €178.8K from €146.4K a year earlier, equity rose to €145.2K, and liabilities increased to €45.4K. The equity ratio stood at 81.2%, with debt-to-equity at 0.31. Return on equity was 3.4% and return on assets 2.7%, while asset turnover reached 2.46x. Revenue per employee was €219.8K and profit per employee €2.4K, indicating moderate operating efficiency in 2025.